Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2), also known as ILT4, is an inhibitory immune receptor primarily expressed on myelomonocytic cells. It binds to both classical and non-classical MHC class I molecules and β-Amyloid, transducing inhibitory signals via ITIMs. LILRB2 plays a role in immune regulation, inflammation control, cancer progression, and neurodegeneration associated with Alzheimer's disease.
Inhibits activation of immune responses by downregulating co-stimulatory molecules on dendritic cells. Promotes tolerogenic properties in dendritic cells leading to T cell anergy. Transduces inhibitory signals upon ligand binding via ITIMs that recruit phosphatases such as SHP-1.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2).